18 July 2014
EMA/447799/2014
Human Medicines Development and Evaluation

Public statement on Revasc

Withdrawal of the marketing authorisation in the European Union

On 09 July 1997, the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Revasc, which had been approved for prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.

The marketing authorisation holder (MAH) responsible for Revasc was Canyon Pharmaceuticals Limited.

On 18 July 2014, the European Commission issued a decision to withdraw the marketing authorisation for Revasc, following its receipt of a letter dated 19 June 2014 notifying the Commission of the MAH's decision to voluntarily withdraw the marketing authorisation for this product for commercial reason.

Revasc was not marketed in any European country.

Pursuant to this decision, the European public assessment report for Revasc will be updated to reflect that the marketing authorisation is no longer valid.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8613
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union